Tetra Bio-Pharma Receives Funding from the Government of Canada for ARDS-003


  • The Company is receiving up to
    $150,000 in funding from the National Research Council of Canada
    Industrial Research Assistance Program (NRC IRAP)

    to support the development of its novel
    oral therapeutic for systemic hyperinflammation.



March 3, 2023 – Tetra Bio-Pharma Inc.
(“Tetra” or the “Company”) (TSX:TBP) (OTC:TBPMF)
(FRA:JAM1), a leader in cannabinoid-derived drug discovery and
development is excited to announce it is receiving

up to
$150,000 in funding from the National Research Council of Canada
Industrial Research Assistance Program (NRC IRAP) to support a
research and development project to enable the development of its
ARDS-003 oral formulation. Specifically, the funds will be used to
optimize the formulation and perform animal non-GLP Pharmacokinetic

In August 2022, Tetra responded to a “

Respiratory Disease Therapeutics

Challenge sponsored by the
National Research Council of Canada (NRC) through the Innovative
Solutions Canada program seeking potential therapeutics to treat
respiratory diseases by targeting viral infection, replication and/or
address associated co-morbidities. The Company was subject to several
diligent evaluations by the NRC to validate its scientific, financial,
and commercial capabilities.

Dr. Guy Chamberland, CEO and Chief Regulatory Officer at Tetra,
commented, “We are grateful to receive this funding which will
support the development of the ARDS-003 oral program by investigating
safety, pharmacokinetics, and pharmacodynamics of novel ARDS-003 oral
formulation. Eligible companies who successfully complete this
Challenge could be considered for additional funding of up to $1M.”

In addition to this funding from the Government of Canada, Tetra
received $4.5M in support from the Government of Quebec for the
clinical development of ARDS-003 in the indication of acute
respiratory distress syndrome, whether or not it is caused by
COVID-19, as well as in patients with sepsis.

A Promising Treatment

ARDS-003 is a novel First in Human (FIH) drug product containing the
active pharmaceutical agent, Onternabez, a potent and selective full
agonist of the type 2 cannabinoid receptor (CB2R), an essential
immunomodulatory target. ARDS-003 is positioned to modulate acute
systemic inflammation and prevent sepsis, ARDS, and organ damage.
 While the clinical profile of ARDS arising from viral (COVID) or
bacterial sepsis can vary, hyperinflammation involving a dysfunctional
immune response is a common mediator of lung damage. Tetra’s
pre-clinical studies have demonstrated that ARDS-003 decreases this
hyperinflammatory response and slows disease progression.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX: TBP) (OTC-Pink: TBPMF) (FRA: JAM1) is a leader
in cannabinoid-derived drug discovery and development with a FDA and a
Health Canada cleared clinical program aimed at bringing novel
prescription drugs and treatments to patients and their healthcare
providers. Their evidence-based scientific approach has enabled them
to develop a pipeline of cannabinoid-based drug products for a range
of medical conditions, including pain, inflammation, and oncology.
With patients at the core of what they do, Tetra Bio-Pharma is focused
on providing rigorous scientific validation and safety data required
for inclusion into the existing biopharma industry by regulators,
physicians and insurance companies.

Connect with Tetra:








Neither the TSX Exchange nor its
Regulation Services Provider (as that term is defined in the policies
of the TSX Exchange) accepts responsibility for the adequacy or
accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking
information. All statements, other than of historical fact, that
address activities, events or developments that the Company believes,
expects or anticipates will or may occur in the future (including,
without limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking statements
are generally identifiable by use of the words “may”,
“will”, “should”, “continue”,
“expect”, “anticipate”, “estimate”,
“believe”, “intend”, “plan” or
“project” or the negative of these words or other variations
on these words or comparable terminology. Forward-looking statements
are subject to a number of risks and uncertainties, many of which are
beyond the Company’s ability to control or predict, that may cause the
actual results of the Company to differ materially from those
discussed in the forward-looking statements. Factors that could cause
actual results or events to differ materially from current
expectations include, among other things, without limitation, the
inability of the Company to obtain sufficient financing to execute the
Company’s business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company’s research
and development strategies, including the success of this product  or
any other product, the applicability of the discoveries made therein,
the successful and timely completion and uncertainties related to the
regulatory process, the timing of clinical trials, the timing and
outcomes of regulatory or intellectual property decisions and other
risks disclosed in the Company’s public disclosure record on file with
the relevant securities regulatory authorities. Although the Company
has attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking statements.
The forward-looking statements included in this news release are made
as of the date of this news release and the Company does not undertake
an obligation to publicly update such forward-looking statements to
reflect new information, subsequent events or otherwise unless
required by applicable securities legislation.

For further information, please
contact Tetra Bio-Pharma Inc.:

Ms. Natalie Leroux

Phone: + 1 (833) 977-7575



SOURCE Tetra Bio-Pharma Inc.

Copyright (c) 2023 TheNewswire – All rights reserved.

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *